Q1 sales fell due to “significantly lower demand” for COVID-19 tests, however new eye drug Vabysmo helped temper the drop. The Swiss pharma giant also confirmed its FY023 outlook. Q1 Group sales …
Read Full Story at source (may require registration)
- European Shares Drift Lower Amid France’s Debt Woes - November 27, 2024
- FTSE 100 Modestly Higher In Cautious Trade - November 27, 2024
- CAC 40 Slides As French Risk Premium Peaks - November 27, 2024